Results 221 to 230 of about 1,650,972 (414)

Automated rapidplan model validation using Eclipse scripting API

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract RapidPlan offers efficiency gains and quality improvements in treatment planning. Prior to its use in the clinic, it requires an extensive validation procedure in which established clinical plans and those generated by the model are compared. The manual iterative nature of this process is resource intensive, as numerous iterations are required
Bradley Beeksma   +2 more
wiley   +1 more source

Settlement in modern network-based payment infrastructures – description and prototype of the E-Settlement model [PDF]

open access: yes
Payment systems are undergoing rapid and fundamental changes stimulated largely by technological progress especially distributed network technology and real-time processing.
Leinonen, Harry   +2 more
core  

Short‐chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profile

open access: yesAnnals of Clinical and Translational Neurology, Volume 12, Issue 3, Page 478-490, March 2025.
Abstract Objective An alteration in the composition of the intestinal microbiota has been observed in patients with multiple sclerosis (pwMS) with respect to healthy controls (HC). Microorganism‐derived metabolites such as short‐chain fatty acids (SCFA) have been suggested to play a role in the disease.
Maria Inmaculada Dominguez‐Mozo   +18 more
wiley   +1 more source

Payments and Mechanism Design [PDF]

open access: yes
We use mechanism design to study efficient intertemporal payment arrangements when the ability of agents to perform certain welfare-improving transactions is subject to random and unobservable shocks.
Cyril Monnet   +2 more
core  

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy